Dr. Galsky on a Post-Treatment Nomogram in Urothelial Cancer

Matthew D. Galsky, MD, from the Mount Sinai Medical Center Tisch Cancer Institute, discusses the development of a post-treatment prognostic model for patients with metastatic urothelial cancer.

Matthew D. Galsky, MD, director, Genitourinary Medical Oncology, associate medical director, Cancer Clinical Trials Office, Mount Sinai Medical Center, The Tisch Cancer Institute, discusses the development of a post-treatment prognostic model following treatment with first-line chemotherapy for patients with metastatic urothelial cancer.

Data was pooled from 317 patients who were enrolled in 8 clinical trials that were evaluating first-line cisplatin in metastatic urothelial cancer. To create the post-treatment nomogram, established pretreatment variables were combined with response to treatment, the duration of chemotherapy, and the reason for stopping treatment.

The duration of treatment and treatment discontinuation were not found to correlate with changes in survival, Galsky notes. Overall, the only post-treatment factor that was associated with survival was response to chemotherapy. Following an independent validation, the nomogram contained 4 indicators: response to chemotherapy, number of visceral metastatic sites, ECOG performance status, and whole blood cell counts.

Galsky believes these findings are particularly important for patients who want to know what comes next after treatment. Additionally, it may help select patients who are eligible to participate in maintenance therapy trials.

Related Videos
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Alastair Thompson, BSc, MBChB, MD, FRCS
C. Ola Landgren, MD, PhD
Sara M. Tolaney, MD, MPH
Adam M. Brufsky, MD, PhD, FACP
Justin M. Watts, MD
Sara M. Tolaney, MD, MPH
Leah Backhus, MD, MPH, FACS, professor, University Medical Line, Cardiothoracic Surgery, co-director, Thoracic Surgery Clinical Research Program, associate program director, Thoracic Track, CT Surgery Residency Training Program, Thelma and Henry Doelger Professor of Cardiovascular Surgery, Stanford Medicine; chief, Thoracic Surgery, VA Palo Alto
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Medical Oncology, director, Center for Thoracic Cancers, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine